Pharma Insight ApS: Financial statements 2025
CVR: 40637117
Source: annual report 2025, Danish Business Authority
01/01/2025 – 31/12/2025
Pharma Insight ApS (CVR 40637117) has filed annual accounts for 2025. In 2025, the company reported a gross profit of DKK 342,207 and a net result of DKK 265,159 compared with DKK 117,750 the year before. That is an increase of 147.2% compared with the year before. Equity in the 2025 report amounted to DKK 340,254. The solvency ratio was 70.3%.
- Gross Profit
- DKK 342,207
- Profit/Loss
- DKK 265,159
- Equity
- DKK 340,254
- Total Assets
- DKK 484,131
- Employees
- 0
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2025 | - | 342 t. | 265 t. | 340 t. | 0 |
| 2024 | - | 138 t. | 118 t. | 145 t. | 0 |
| 2023 | - | -17 t. | -19 t. | 27 t. | 0 |
| 2022 | - | -27 t. | -27 t. | 146 t. | 1 |
| 2021 | - | 725 t. | 48 t. | 273 t. | 1 |
Official annual report
How creditworthy is Pharma Insight ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2025
Pharma Insight ApS has published its annual report for 2024. Gross profit came to DKK 138,457, and the net result was DKK 117,750.
About Pharma Insight ApS
Pharma Insight ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2019. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Marianne Kock and Peter Kock. The company is owned by Peter Kock Holding ApS. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 342,207 and a net result of DKK 265,159 compared with DKK 117,750 the year before. Equity in the 2025 report amounted to DKK 340,254.